Asset profile
Epcoritamab
Multispecific antibody
Approved / Phase 4Mechanism not established
Approvedregulatory verdict
Evidence outlook
Approved: Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
2 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 2 same-indication.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Epcoritamab: this drug | Approved | Multispecific antibody | — | ||
| Tafasitamab | Approved | Monoclonal antibody | — | ||
| CTX112 | Phase 1/2 | Biologic (subtype unspecified) | CD19 |
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(49 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (2)
November 2026 (1)
Phase 2DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements …Recruiting
Est. primary completion 2026-11 · NCT06287398 · CT.gov ↗
What to watch
December 2026 (1)
Phase 1Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2026-12-31 · NCT06672705 · CT.gov ↗
What to watch
2027 (15)
February 2027 (1)
Phase 2Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder …Recruiting
Est. primary completion 2027-02-18 · NCT06723457 · CT.gov ↗
What to watch
March 2027 (1)
Phase 2Diffuse Large B-Cell LymphomaActive not recruiting
Est. primary completion 2027-03 · NCT05451810 · CT.gov ↗
What to watch
April 2027 (1)
Phase 2Waldenstrom Macroglobulinemia, B-Cell Lymphoproliferative DisorderRecruiting
Est. primary completion 2027-04-30 · NCT06510491 · CT.gov ↗
What to watch
June 2027 (1)
Phase 3Diffuse Large B-Cell LymphomaActive not recruiting
Est. primary completion 2027-06 · NCT05578976 · CT.gov ↗
What to watch
July 2027 (2)
Phase 1Leukemia, Chronic Lymphocytic, Richter SyndromeActive not recruiting
Est. primary completion 2027-07-01 · NCT06676033 · CT.gov ↗
What to watch
Phase 2CLL/SLL, CLL, SLL, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma Variant …Recruiting
Est. primary completion 2027-07-01 · NCT07108998 · CT.gov ↗
What to watch
August 2027 (2)
September 2027 (3)
Phase 1/2Follicular LymphomaActive not recruiting
Est. primary completion 2027-09 · NCT04542824 · CT.gov ↗
What to watch
Phase 2Relapsed/Refractory Diffuse Large B Cell LymphomaRecruiting
Est. primary completion 2027-09 · NCT07451652 · CT.gov ↗
What to watch
Phase 1/2Diffuse Large B-Cell LymphomaActive not recruiting
Est. primary completion 2027-09-30 · NCT04663347 · CT.gov ↗
What to watch
October 2027 (2)
November 2027 (1)
Phase 2Large Cell Lymphoma, Diffuse, Relapsed Cancer, Refractory CancerRecruiting
Est. primary completion 2027-11-24 · NCT05852717 · CT.gov ↗
What to watch
December 2027 (1)
Phase 1/2Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome …Active not recruiting
Est. primary completion 2027-12 · NCT04623541 · CT.gov ↗
What to watch
2028 (13)
January 2028 (1)
Phase 2Primary CNS Lymphoma (PCNSL)Recruiting
Est. primary completion 2028-01 · NCT06931652 · CT.gov ↗
What to watch
February 2028 (1)
Phase 2Follicular LymphomaRecruiting
Est. primary completion 2028-02 · NCT05783609 · CT.gov ↗
What to watch
March 2028 (1)
Phase 3Diffuse Large B-Cell LymphomaActive not recruiting
Est. primary completion 2028-03 · NCT06508658 · CT.gov ↗
What to watch
July 2028 (3)
Phase 2Diffuse Large B-Cell LymphomaNot yet recruiting
Est. primary completion 2028-07 · NCT07814001 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2028-07-01 · NCT06905509 · CT.gov ↗
What to watch
Phase 2Large B-cell LymphomaRecruiting
Est. primary completion 2028-07-31 · NCT06045247 · CT.gov ↗
What to watch
August 2028 (2)
Phase 1Primary Central Nervous System Lymphoma (PCNSL), Primary Central Nervous System Lymphoma, Relapsed Primary Central Nervous System Lymphoma …Recruiting
Est. primary completion 2028-08 · NCT07082868 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-Cell LymphomaNot yet recruiting
Est. primary completion 2028-08-31 · NCT07588698 · CT.gov ↗
What to watch
September 2028 (1)
Phase 1Non-Hodgkin Lymphoma, Cytokine Release SyndromeRecruiting
Est. primary completion 2028-09-01 · NCT06447376 · CT.gov ↗
What to watch
October 2028 (2)
Phase 2CLL, CLL (Chronic Lymphocytic Leukemia), Chronic Lymphocytic Leukemia (CLL), BTKiNot yet recruiting
Est. primary completion 2028-10 · NCT07819214 · CT.gov ↗
What to watch
Phase 2Marginal Zone Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Splenic Marginal Zone Lymphoma …Recruiting
Est. primary completion 2028-10-15 · NCT06796998 · CT.gov ↗
What to watch
November 2028 (1)
Phase 1Non-hodgkin LymphomaActive not recruiting
Est. primary completion 2028-11 · NCT05206357 · CT.gov ↗
What to watch
December 2028 (1)
Phase 2Follicular LymphomaNot yet recruiting
Est. primary completion 2028-12-31 · NCT07783594 · CT.gov ↗
What to watch
2029 (8)
January 2029 (1)
Phase 1/2DLBCL, High-grade B-cell Lymphoma (HGBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), FL, MCL, Small Lymphocytic Lymphoma (SLL) …Active not recruiting
Est. primary completion 2029-01 · NCT03625037 · CT.gov ↗
What to watch
March 2029 (1)
May 2029 (1)
Phase 2Follicular LymphomaRecruiting
Est. primary completion 2029-05-31 · NCT05848765 · CT.gov ↗
What to watch
June 2029 (1)
Phase 2Chronic Lymphocytic Leukemia, Small Lymphocytic LymphomaRecruiting
Est. primary completion 2029-06-08 · NCT07218510 · CT.gov ↗
What to watch
October 2029 (1)
Phase 2Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2029-10-15 · NCT07365306 · CT.gov ↗
What to watch
December 2029 (3)
Phase 3Follicular LymphomaActive not recruiting
Est. primary completion 2029-12 · NCT05409066 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2029-12-31 · NCT06238648 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic Leukemia, Small Lymphocytic LymphomaNot yet recruiting
Est. primary completion 2029-12-31 · NCT07738887 · CT.gov ↗
What to watch
2030 (5)
March 2030 (1)
Phase 2Follicular LymphomaRecruiting
Est. primary completion 2030-03-01 · NCT06563596 · CT.gov ↗
What to watch
April 2030 (1)
Phase 2Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2030-04-30 · NCT07197307 · CT.gov ↗
What to watch
May 2030 (1)
Phase 2Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2030-05-31 · NCT07097363 · CT.gov ↗
What to watch
June 2030 (1)
Phase 1Diffuse Large B Cell LymphomaRecruiting
Est. primary completion 2030-06 · NCT07528352 · CT.gov ↗
What to watch
October 2030 (1)
Phase 1Diffuse Large B-Cell LymphomaNot yet recruiting
Est. primary completion 2030-10-08 · NCT07714421 · CT.gov ↗
What to watch
2031 (4)
January 2031 (1)
Phase 2Large B-cell Lymphoma, RelapseRecruiting
Est. primary completion 2031-01-07 · NCT06919939 · CT.gov ↗
What to watch
May 2031 (1)
Phase 2Adult Burkitt LymphomaNot yet recruiting
Est. primary completion 2031-05-30 · NCT07662928 · CT.gov ↗
What to watch
September 2031 (1)
Phase 1/2Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-cell Non-Hodgkin LymphomaRecruiting
Est. primary completion 2031-09-30 · NCT07283679 · CT.gov ↗
What to watch
December 2031 (1)
Phase 2Large B Cell LymphomaRecruiting
Est. primary completion 2031-12-27 · NCT07126236 · CT.gov ↗
What to watch
2032 (1)
November 2032 (1)
Phase 2Non-Hodgkin LymphomaActive not recruiting
Est. primary completion 2032-11 · NCT05283720 · CT.gov ↗
What to watch
2037 (1)
November 2037 (1)
Phase 3Follicular LymphomaActive not recruiting
Est. primary completion 2037-11 · NCT06191744 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.